Vivek Ramaswamy

And the way I made my money was that five of those drugs that we developed through phase three and successful phase three studies went on to become FDA approved. And the one I'm probably most proud of is a drug actually for the smallest of those markets.

And the way I made my money was that five of those drugs that we developed through phase three and successful phase three studies went on to become FDA approved. And the one I'm probably most proud of is a drug actually for the smallest of those markets.

But there is a disease where 20 kids a year are born with this genetic condition where 100% of those kids die by the age of three if they're untreated. And because of the therapy that we led all the way to get through approval in phase three, about 70% of those kids live lives of normal duration.

But there is a disease where 20 kids a year are born with this genetic condition where 100% of those kids die by the age of three if they're untreated. And because of the therapy that we led all the way to get through approval in phase three, about 70% of those kids live lives of normal duration.

But there is a disease where 20 kids a year are born with this genetic condition where 100% of those kids die by the age of three if they're untreated. And because of the therapy that we led all the way to get through approval in phase three, about 70% of those kids live lives of normal duration.

Another for endometriosis, for uterine fibroids, women's health conditions that were generally ignored by pharma. So those were the areas that we had success. Five out of how many, you think? There's many more that are still in development, but there were... probably 20 drugs that we've put into development, 20 plus, many of which are still in the development process.

Another for endometriosis, for uterine fibroids, women's health conditions that were generally ignored by pharma. So those were the areas that we had success. Five out of how many, you think? There's many more that are still in development, but there were... probably 20 drugs that we've put into development, 20 plus, many of which are still in the development process.

Another for endometriosis, for uterine fibroids, women's health conditions that were generally ignored by pharma. So those were the areas that we had success. Five out of how many, you think? There's many more that are still in development, but there were... probably 20 drugs that we've put into development, 20 plus, many of which are still in the development process.

But five of them ended up going through phase three, successful, sold those rights to other pharma companies, generated billions of dollars in value for shareholders. And the company I founded, Roivant, is like a $8, $9, $10 billion publicly traded company on the NASDAQ today that's returned billions of dollars to shareholders. And I'm proud of that.

But five of them ended up going through phase three, successful, sold those rights to other pharma companies, generated billions of dollars in value for shareholders. And the company I founded, Roivant, is like a $8, $9, $10 billion publicly traded company on the NASDAQ today that's returned billions of dollars to shareholders. And I'm proud of that.

But five of them ended up going through phase three, successful, sold those rights to other pharma companies, generated billions of dollars in value for shareholders. And the company I founded, Roivant, is like a $8, $9, $10 billion publicly traded company on the NASDAQ today that's returned billions of dollars to shareholders. And I'm proud of that.

And it was a very cool company that bucked the trend of pharma. And a lot of people in big pharma didn't like it because it in some ways made traditional big pharma look bad because it called the bluff on a lot of these areas they were ignoring. And that's how the company succeeded. Oh, so you think there's like a smear campaign for exposing that?

And it was a very cool company that bucked the trend of pharma. And a lot of people in big pharma didn't like it because it in some ways made traditional big pharma look bad because it called the bluff on a lot of these areas they were ignoring. And that's how the company succeeded. Oh, so you think there's like a smear campaign for exposing that?

And it was a very cool company that bucked the trend of pharma. And a lot of people in big pharma didn't like it because it in some ways made traditional big pharma look bad because it called the bluff on a lot of these areas they were ignoring. And that's how the company succeeded. Oh, so you think there's like a smear campaign for exposing that?

Well, I think initially a lot of pharmas did not like Roivant's existence. That's definitely true. But when I entered the realm of politics, which is the realm of smear campaigns, there was definitely a concerted effort to exploit one of the drugs that failed. That's the Alzheimer's drug. That's the Alzheimer's drug. Right. So we had a subsidiary called Axaman.

Well, I think initially a lot of pharmas did not like Roivant's existence. That's definitely true. But when I entered the realm of politics, which is the realm of smear campaigns, there was definitely a concerted effort to exploit one of the drugs that failed. That's the Alzheimer's drug. That's the Alzheimer's drug. Right. So we had a subsidiary called Axaman.

Well, I think initially a lot of pharmas did not like Roivant's existence. That's definitely true. But when I entered the realm of politics, which is the realm of smear campaigns, there was definitely a concerted effort to exploit one of the drugs that failed. That's the Alzheimer's drug. That's the Alzheimer's drug. Right. So we had a subsidiary called Axaman.

It was developing a drug for Alzheimer's disease. So Roivin is the subsidiary of Axaman. Ended up being sold for a big premium. Immune event, took it public. Trades at a big premium to where it went public. Eurovent, a bunch of them. It was acquired for a big premium. Accident was one of those companies, was a subsidiary of Roivin, that developed this drug for Alzheimer's disease.

It was developing a drug for Alzheimer's disease. So Roivin is the subsidiary of Axaman. Ended up being sold for a big premium. Immune event, took it public. Trades at a big premium to where it went public. Eurovent, a bunch of them. It was acquired for a big premium. Accident was one of those companies, was a subsidiary of Roivin, that developed this drug for Alzheimer's disease.

It was developing a drug for Alzheimer's disease. So Roivin is the subsidiary of Axaman. Ended up being sold for a big premium. Immune event, took it public. Trades at a big premium to where it went public. Eurovent, a bunch of them. It was acquired for a big premium. Accident was one of those companies, was a subsidiary of Roivin, that developed this drug for Alzheimer's disease.